Drug profile

Here's what the FDA CVM extract says about Fluralaner For Extended Release Injectable Suspension

The CVM extract lists 20 reports for Fluralaner For Extended Release Injectable Suspension, a lower-volume entry. Species, reactions, and outcomes are below.

#1795 of 2,679
by report volume (all drugs)
20
adverse-event reports
5.0%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Fluralaner For Extended Release Injectable Suspension ranks #1778 of 2679 by total reports (20). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1778
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Signature read: death-coded report count at 1 is the most distinctive stamp on Fluralaner For Extended Release Injectable Suspension's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
20
Total Reports
1
Deaths Reported
5.0%
Death-coded share of reports

Active Ingredients

Fluralaner For Extended Release Injectable Suspension

Administration Routes

UnknownSubcutaneous

Species Affected

Dog 20

Most Affected Breeds

Retriever - Labrador 5
Terrier - Bull - American Pit 3
Retriever - Golden 2
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1
Bichon Frise 1
Terrier - Bull - Staffordshire 1
Bulldog - French 1
Terrier (unspecified) 1
Spitz - German Pomeranian 1
Great Pyrenees 1

Most Reported Reactions

Hives (see also Skin) 6
Lethargy (see also Central nervous system depression in Neurological) 6
Vomiting 5
Facial swelling (see also Skin) 4
Not eating 4
Medication error NOS 3
Emesis (multiple) 3
Hypersensitivity NOS 2
Not himself/herself 2
Weight loss 2
Anaemia NOS 2
Hypersensitivity reaction 2

Outcome Breakdown

Ongoing
10 (50.0%)
Recovered/Normal
6 (30.0%)
Outcome Unknown
3 (15.0%)
Euthanized
1 (5.0%)

Fluralaner For Extended Release Injectable Suspension: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Where to go from here

  • Before drawing conclusions from this number, read why death-coded share is not the same thing as a mortality rate. Understanding adverse events
  • Browse the full drug directory to compare report counts across products. All drugs

Correlation in adverse-event counts is not causation; consult a veterinarian before making a decision from this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Fluralaner For Extended Release Injectable Suspension (#1795 of 2,679 by report volume); death-coded 5.0%. PlainBreed drug row · death-coded report count stamp 1 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →